Abstract
Minnesota is home to two of the pioneering institutions that ushered in the golden era of modern cardiac surgery. Clinicians and researchers at the Mayo Clinic and the University of Minnesota built on this momentum and began translating clinical research directly to the bedside. This legacy continues today. Minnesota has a rich history and track record of translating clinical research to the bedside and developing medical device companies that have benefited investigators, patients, and the economy. We will give a brief overview of this model and the steps to success which can be duplicated by other states and countries.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 292-294 |
| Number of pages | 3 |
| Journal | Journal of cardiovascular translational research |
| Volume | 1 |
| Issue number | 4 |
| DOIs | |
| State | Published - Dec 2008 |
Bibliographical note
Funding Information:However, equally important to financial support from the NIH is matching funds from philanthropic donors. Why? The manner in which science is being conducted is changing and the NIH model will not and should not be expected to fill this gap. Technology is advancing, population studies are larger, and the best and the brightest researchers are coming together to build consortiums and challenge medicine as we know it today. Philanthropic/private foundations and donors work very hard for the most successful return on their investment. If they are going to invest, they want the best technology, the largest population/best designed study, and the best and brightest researchers working together on their team. This mindset of investing in the best ensures confidence and success. The researchers feel this change and instead of working towards a progress report, they work towards success.
Funding Information:
Researchers within the state are supported by the National Institute of Health (NIH) as well as other public and private foundations. Financial support from the NIH, the American Heart Association, and others is critical for the advancement of the field. The State of Minnesota is currently an active participant in the Cardiovascular Cell Therapy Research Network (RFA-HL-06-001). The state is also a participant in the Heart Failure Clinical Research Network (RFA-HL-05-003). The goal of these networks is to accelerate research diagnosis and management to improve outcome through optimal application of existing therapies